Clinical Trial Update: Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports repeat dosing of BAY1902607 in healthy males and a proof-of-concept in chronic cough patients across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• BAY1902607 (BAY1902607)

Snippet

Sponsor: Bayer | Conditions: Cough | Phase 1, Phase 2 | Status: COMPLETED